SCHEDULE: AdvisorShares Trust Discloses 6.69% Stake in Silo Pharma

AdvisorShares Trust has reported beneficial ownership of 75,582 shares, representing 6.69% of Silo Pharma, Inc.'s common stock, as of June 30, 2026.

Summary

• AdvisorShares Trust has filed a Schedule 13G, indicating it beneficially owns 75,582 shares of Silo Pharma, Inc. common stock.
• This ownership stake represents 6.69% of the total class of securities.
• The filing date for this event is June 30, 2026.
• AdvisorShares Trust holds sole voting power and sole dispositive power over these shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of beneficial ownership by an investment trust and does not inherently signal positive or negative performance for Silo Pharma, Inc.

Positives

• AdvisorShares Trust's significant stake (6.69%) suggests confidence in Silo Pharma's potential.
• The acquisition of shares in the ordinary course of business indicates a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not provide details on the acquisition cost or the specific investment strategy behind acquiring the stake.

Risks

• Potential for increased market volatility if AdvisorShares Trust decides to significantly alter its position.
• The concentration of ownership could influence corporate decisions, potentially impacting minority shareholders if not aligned with their interests.

Future Outlook

The filing does not contain forward-looking statements or guidance from Silo Pharma, Inc. It solely reports the beneficial ownership of AdvisorShares Trust.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by an entity like AdvisorShares Trust, which manages investment funds, typically signifies a passive investment approach. This filing indicates AdvisorShares Trust has crossed the 5% ownership threshold in Silo Pharma, Inc., a common trigger for such disclosures, and is not seeking to control the company.

Stakeholder Impact

• Shareholders: May view the increased institutional interest as a positive sign, but the passive nature of the filing suggests no immediate change in corporate strategy.
• Management: Will be aware of AdvisorShares Trust's significant stake and its implications for shareholder engagement, though no control is being sought.
• Creditors: Unlikely to be directly impacted by this filing as it pertains to equity ownership and not debt.

Next Steps

• Monitor future filings from AdvisorShares Trust for any changes in its beneficial ownership of Silo Pharma, Inc.
• Observe Silo Pharma, Inc.'s stock performance and corporate actions for potential impacts of this ownership disclosure.

Key Dates

Keywords

Silo Pharma, AdvisorShares Trust, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Shareholder